

Global Biologics and Biosimilars CXO Services Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/GDFF12F7397BEN.html>

Date: March 2026

Pages: 184

Price: US\$ 3,660.00 (Single User License)

ID: GDFF12F7397BEN

Abstracts

The global Biologics and Biosimilars CXO Services market size is predicted to grow from US\$ 62320 million in 2025 to US\$ 111390 million in 2032; it is expected to grow at a CAGR of 8.8% from 2026 to 2032.

Biologics and Biosimilars CXO services have gained significant importance as the complexity of biologics and biosimilars development continues to grow. By outsourcing specialized tasks such as clinical trials, process development, and large-scale biologic manufacturing, biopharmaceutical companies can focus on core innovations and strategic growth. This collaboration not only streamlines the drug development pipeline but also ensures compliance with regulatory standards, enhancing the overall efficiency and reducing time-to-market for breakthrough biologic therapies.

United States market for Biologics and Biosimilars CXO Services is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Biologics and Biosimilars CXO Services is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Biologics and Biosimilars CXO Services is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Biologics and Biosimilars CXO Services players cover Catalent, Thermo Fisher Scientific, Lonza, Siegfried, Recipharm, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LPI (LP Information)' newest research report, the “Biologics and Biosimilars CXO Services Industry Forecast” looks at past sales and reviews total world Biologics and Biosimilars CXO Services sales in 2025, providing a comprehensive analysis by region and market sector of projected Biologics and Biosimilars CXO Services sales for 2026 through 2032. With Biologics and Biosimilars CXO Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Biologics and Biosimilars CXO Services industry.

This Insight Report provides a comprehensive analysis of the global Biologics and Biosimilars CXO Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Biologics and Biosimilars CXO Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Biologics and Biosimilars CXO Services market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biologics and Biosimilars CXO Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biologics and Biosimilars CXO Services.

This report presents a comprehensive overview, market shares, and growth opportunities of Biologics and Biosimilars CXO Services market by product type, application, key players and key regions and countries.

Segmentation by Type:

CRO

CDMO/CMO

CSO

Segmentation by Application:

API CXO

FDF CXO

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Catalent

Thermo Fisher Scientific

Lonza

Siegfried

Recipharm

Boehringer Ingelheim

WuXi AppTech

WuXi Biologics

Fareva

Samsung Biologics

Aenova

Delpharm

Strides Pharma

Piramal

Famar

Curia

Jubilant

Vetter

AGC Pharma Chemicals

Asymchem

Pharmaron

Eurofins

Ascendia Pharmaceuticals

Ardena

CPL

UPM Pharmaceuticals

FUJIFILM Diosynth Biotechnologies

Groupe Parima

TBD Pharmatech

Avid Bioservices

NextPharma

Alcami

Societal CDMO

MedPharm

Euroapi

BioVectra

Pfizer CentreOne

Fermion

The report requires updating with new data and is sent in 48 hours after order is placed.

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Biologics and Biosimilars CXO Services Market Size (2021-2032)
- 2.1.2 Biologics and Biosimilars CXO Services Market Size CAGR by Region (2021 VS 2025 VS 2032)
- 2.1.3 World Current & Future Analysis for Biologics and Biosimilars CXO Services by Country/Region (2021, 2025 & 2032)

2.2 Biologics and Biosimilars CXO Services Segment by Type

- 2.2.1 CRO
- 2.2.2 CDMO/CMO
- 2.2.3 CSO
- 2.2.4 Biologics and Biosimilars CXO Services Market Size by Type
 - 2.2.4.1 Biologics and Biosimilars CXO Services Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.4.2 Global Biologics and Biosimilars CXO Services Market Size Market Share by Type (2021-2026)

2.3 Biologics and Biosimilars CXO Services Segment by Application

- 2.3.1 API CXO
- 2.3.2 FDF CXO
- 2.3.3 Other
- 2.3.4 Biologics and Biosimilars CXO Services Market Size by Application
 - 2.3.4.1 Biologics and Biosimilars CXO Services Market Size CAGR by Application (2021 VS 2025 VS 2032)
 - 2.3.4.2 Global Biologics and Biosimilars CXO Services Market Size Market Share by Application (2021-2026)

3 BIOLOGICS AND BIOSIMILARS CXO SERVICES MARKET SIZE BY PLAYER

3.1 Biologics and Biosimilars CXO Services Market Size Market Share by Player

3.1.1 Global Biologics and Biosimilars CXO Services Revenue by Player (2021-2026)

3.1.2 Global Biologics and Biosimilars CXO Services Revenue Market Share by Player (2021-2026)

3.2 Global Biologics and Biosimilars CXO Services Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 BIOLOGICS AND BIOSIMILARS CXO SERVICES BY REGION

4.1 Biologics and Biosimilars CXO Services Market Size by Region (2021-2026)

4.2 Global Biologics and Biosimilars CXO Services Annual Revenue by Country/Region (2021-2026)

4.3 Americas Biologics and Biosimilars CXO Services Market Size Growth (2021-2026)

4.4 APAC Biologics and Biosimilars CXO Services Market Size Growth (2021-2026)

4.5 Europe Biologics and Biosimilars CXO Services Market Size Growth (2021-2026)

4.6 Middle East & Africa Biologics and Biosimilars CXO Services Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Biologics and Biosimilars CXO Services Market Size by Country (2021-2026)

5.2 Americas Biologics and Biosimilars CXO Services Market Size by Type (2021-2026)

5.3 Americas Biologics and Biosimilars CXO Services Market Size by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

- 6.1 APAC Biologics and Biosimilars CXO Services Market Size by Region (2021-2026)
- 6.2 APAC Biologics and Biosimilars CXO Services Market Size by Type (2021-2026)
- 6.3 APAC Biologics and Biosimilars CXO Services Market Size by Application (2021-2026)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

7 EUROPE

- 7.1 Europe Biologics and Biosimilars CXO Services Market Size by Country (2021-2026)
- 7.2 Europe Biologics and Biosimilars CXO Services Market Size by Type (2021-2026)
- 7.3 Europe Biologics and Biosimilars CXO Services Market Size by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Biologics and Biosimilars CXO Services by Region (2021-2026)
- 8.2 Middle East & Africa Biologics and Biosimilars CXO Services Market Size by Type (2021-2026)
- 8.3 Middle East & Africa Biologics and Biosimilars CXO Services Market Size by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL BIOLOGICS AND BIOSIMILARS CXO SERVICES MARKET FORECAST

10.1 Global Biologics and Biosimilars CXO Services Forecast by Region (2027-2032)

10.1.1 Global Biologics and Biosimilars CXO Services Forecast by Region
(2027-2032)

10.1.2 Americas Biologics and Biosimilars CXO Services Forecast

10.1.3 APAC Biologics and Biosimilars CXO Services Forecast

10.1.4 Europe Biologics and Biosimilars CXO Services Forecast

10.1.5 Middle East & Africa Biologics and Biosimilars CXO Services Forecast

10.2 Americas Biologics and Biosimilars CXO Services Forecast by Country
(2027-2032)

10.2.1 United States Market Biologics and Biosimilars CXO Services Forecast

10.2.2 Canada Market Biologics and Biosimilars CXO Services Forecast

10.2.3 Mexico Market Biologics and Biosimilars CXO Services Forecast

10.2.4 Brazil Market Biologics and Biosimilars CXO Services Forecast

10.3 APAC Biologics and Biosimilars CXO Services Forecast by Region (2027-2032)

10.3.1 China Biologics and Biosimilars CXO Services Market Forecast

10.3.2 Japan Market Biologics and Biosimilars CXO Services Forecast

10.3.3 Korea Market Biologics and Biosimilars CXO Services Forecast

10.3.4 Southeast Asia Market Biologics and Biosimilars CXO Services Forecast

10.3.5 India Market Biologics and Biosimilars CXO Services Forecast

10.3.6 Australia Market Biologics and Biosimilars CXO Services Forecast

10.4 Europe Biologics and Biosimilars CXO Services Forecast by Country (2027-2032)

10.4.1 Germany Market Biologics and Biosimilars CXO Services Forecast

10.4.2 France Market Biologics and Biosimilars CXO Services Forecast

10.4.3 UK Market Biologics and Biosimilars CXO Services Forecast

10.4.4 Italy Market Biologics and Biosimilars CXO Services Forecast

10.4.5 Russia Market Biologics and Biosimilars CXO Services Forecast

10.5 Middle East & Africa Biologics and Biosimilars CXO Services Forecast by Region
(2027-2032)

10.5.1 Egypt Market Biologics and Biosimilars CXO Services Forecast

10.5.2 South Africa Market Biologics and Biosimilars CXO Services Forecast

10.5.3 Israel Market Biologics and Biosimilars CXO Services Forecast

- 10.5.4 Turkey Market Biologics and Biosimilars CXO Services Forecast
- 10.6 Global Biologics and Biosimilars CXO Services Forecast by Type (2027-2032)
- 10.7 Global Biologics and Biosimilars CXO Services Forecast by Application (2027-2032)
 - 10.7.1 GCC Countries Market Biologics and Biosimilars CXO Services Forecast

11 KEY PLAYERS ANALYSIS

11.1 Catalent

- 11.1.1 Catalent Company Information
- 11.1.2 Catalent Biologics and Biosimilars CXO Services Product Offered
- 11.1.3 Catalent Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
- 11.1.4 Catalent Main Business Overview
- 11.1.5 Catalent Latest Developments

11.2 Thermo Fisher Scientific

- 11.2.1 Thermo Fisher Scientific Company Information
- 11.2.2 Thermo Fisher Scientific Biologics and Biosimilars CXO Services Product Offered
- 11.2.3 Thermo Fisher Scientific Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
- 11.2.4 Thermo Fisher Scientific Main Business Overview
- 11.2.5 Thermo Fisher Scientific Latest Developments

11.3 Lonza

- 11.3.1 Lonza Company Information
- 11.3.2 Lonza Biologics and Biosimilars CXO Services Product Offered
- 11.3.3 Lonza Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
- 11.3.4 Lonza Main Business Overview
- 11.3.5 Lonza Latest Developments

11.4 Siegfried

- 11.4.1 Siegfried Company Information
- 11.4.2 Siegfried Biologics and Biosimilars CXO Services Product Offered
- 11.4.3 Siegfried Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
- 11.4.4 Siegfried Main Business Overview
- 11.4.5 Siegfried Latest Developments

11.5 Recipharm

- 11.5.1 Recipharm Company Information

- 11.5.2 Recipharm Biologics and Biosimilars CXO Services Product Offered
- 11.5.3 Recipharm Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
- 11.5.4 Recipharm Main Business Overview
- 11.5.5 Recipharm Latest Developments
- 11.6 Boehringer Ingelheim
 - 11.6.1 Boehringer Ingelheim Company Information
 - 11.6.2 Boehringer Ingelheim Biologics and Biosimilars CXO Services Product Offered
 - 11.6.3 Boehringer Ingelheim Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.6.4 Boehringer Ingelheim Main Business Overview
 - 11.6.5 Boehringer Ingelheim Latest Developments
- 11.7 WuXi AppTech
 - 11.7.1 WuXi AppTech Company Information
 - 11.7.2 WuXi AppTech Biologics and Biosimilars CXO Services Product Offered
 - 11.7.3 WuXi AppTech Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.7.4 WuXi AppTech Main Business Overview
 - 11.7.5 WuXi AppTech Latest Developments
- 11.8 WuXi Biologics
 - 11.8.1 WuXi Biologics Company Information
 - 11.8.2 WuXi Biologics Biologics and Biosimilars CXO Services Product Offered
 - 11.8.3 WuXi Biologics Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.8.4 WuXi Biologics Main Business Overview
 - 11.8.5 WuXi Biologics Latest Developments
- 11.9 Fareva
 - 11.9.1 Fareva Company Information
 - 11.9.2 Fareva Biologics and Biosimilars CXO Services Product Offered
 - 11.9.3 Fareva Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.9.4 Fareva Main Business Overview
 - 11.9.5 Fareva Latest Developments
- 11.10 Samsung Biologics
 - 11.10.1 Samsung Biologics Company Information
 - 11.10.2 Samsung Biologics Biologics and Biosimilars CXO Services Product Offered
 - 11.10.3 Samsung Biologics Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.10.4 Samsung Biologics Main Business Overview

- 11.10.5 Samsung Biologics Latest Developments
- 11.11 Aenova
 - 11.11.1 Aenova Company Information
 - 11.11.2 Aenova Biologics and Biosimilars CXO Services Product Offered
 - 11.11.3 Aenova Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.11.4 Aenova Main Business Overview
 - 11.11.5 Aenova Latest Developments
- 11.12 Delpharm
 - 11.12.1 Delpharm Company Information
 - 11.12.2 Delpharm Biologics and Biosimilars CXO Services Product Offered
 - 11.12.3 Delpharm Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.12.4 Delpharm Main Business Overview
 - 11.12.5 Delpharm Latest Developments
- 11.13 Strides Pharma
 - 11.13.1 Strides Pharma Company Information
 - 11.13.2 Strides Pharma Biologics and Biosimilars CXO Services Product Offered
 - 11.13.3 Strides Pharma Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.13.4 Strides Pharma Main Business Overview
 - 11.13.5 Strides Pharma Latest Developments
- 11.14 Piramal
 - 11.14.1 Piramal Company Information
 - 11.14.2 Piramal Biologics and Biosimilars CXO Services Product Offered
 - 11.14.3 Piramal Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.14.4 Piramal Main Business Overview
 - 11.14.5 Piramal Latest Developments
- 11.15 Famar
 - 11.15.1 Famar Company Information
 - 11.15.2 Famar Biologics and Biosimilars CXO Services Product Offered
 - 11.15.3 Famar Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.15.4 Famar Main Business Overview
 - 11.15.5 Famar Latest Developments
- 11.16 Curia
 - 11.16.1 Curia Company Information
 - 11.16.2 Curia Biologics and Biosimilars CXO Services Product Offered

- 11.16.3 Curia Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
- 11.16.4 Curia Main Business Overview
- 11.16.5 Curia Latest Developments
- 11.17 Jubilant
 - 11.17.1 Jubilant Company Information
 - 11.17.2 Jubilant Biologics and Biosimilars CXO Services Product Offered
 - 11.17.3 Jubilant Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.17.4 Jubilant Main Business Overview
 - 11.17.5 Jubilant Latest Developments
- 11.18 Vetter
 - 11.18.1 Vetter Company Information
 - 11.18.2 Vetter Biologics and Biosimilars CXO Services Product Offered
 - 11.18.3 Vetter Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.18.4 Vetter Main Business Overview
 - 11.18.5 Vetter Latest Developments
- 11.19 AGC Pharma Chemicals
 - 11.19.1 AGC Pharma Chemicals Company Information
 - 11.19.2 AGC Pharma Chemicals Biologics and Biosimilars CXO Services Product Offered
 - 11.19.3 AGC Pharma Chemicals Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.19.4 AGC Pharma Chemicals Main Business Overview
 - 11.19.5 AGC Pharma Chemicals Latest Developments
- 11.20 Asymchem
 - 11.20.1 Asymchem Company Information
 - 11.20.2 Asymchem Biologics and Biosimilars CXO Services Product Offered
 - 11.20.3 Asymchem Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.20.4 Asymchem Main Business Overview
 - 11.20.5 Asymchem Latest Developments
- 11.21 Pharmaron
 - 11.21.1 Pharmaron Company Information
 - 11.21.2 Pharmaron Biologics and Biosimilars CXO Services Product Offered
 - 11.21.3 Pharmaron Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.21.4 Pharmaron Main Business Overview

- 11.21.5 Pharmaron Latest Developments
- 11.22 Eurofins
 - 11.22.1 Eurofins Company Information
 - 11.22.2 Eurofins Biologics and Biosimilars CXO Services Product Offered
 - 11.22.3 Eurofins Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.22.4 Eurofins Main Business Overview
 - 11.22.5 Eurofins Latest Developments
- 11.23 Ascendia Pharmaceuticals
 - 11.23.1 Ascendia Pharmaceuticals Company Information
 - 11.23.2 Ascendia Pharmaceuticals Biologics and Biosimilars CXO Services Product Offered
 - 11.23.3 Ascendia Pharmaceuticals Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.23.4 Ascendia Pharmaceuticals Main Business Overview
 - 11.23.5 Ascendia Pharmaceuticals Latest Developments
- 11.24 Ardena
 - 11.24.1 Ardena Company Information
 - 11.24.2 Ardena Biologics and Biosimilars CXO Services Product Offered
 - 11.24.3 Ardena Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.24.4 Ardena Main Business Overview
 - 11.24.5 Ardena Latest Developments
- 11.25 CPL
 - 11.25.1 CPL Company Information
 - 11.25.2 CPL Biologics and Biosimilars CXO Services Product Offered
 - 11.25.3 CPL Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.25.4 CPL Main Business Overview
 - 11.25.5 CPL Latest Developments
- 11.26 UPM Pharmaceuticals
 - 11.26.1 UPM Pharmaceuticals Company Information
 - 11.26.2 UPM Pharmaceuticals Biologics and Biosimilars CXO Services Product Offered
 - 11.26.3 UPM Pharmaceuticals Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.26.4 UPM Pharmaceuticals Main Business Overview
 - 11.26.5 UPM Pharmaceuticals Latest Developments
- 11.27 FUJIFILM Diosynth Biotechnologies

- 11.27.1 FUJIFILM Diosynth Biotechnologies Company Information
- 11.27.2 FUJIFILM Diosynth Biotechnologies Biologics and Biosimilars CXO Services Product Offered
- 11.27.3 FUJIFILM Diosynth Biotechnologies Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
- 11.27.4 FUJIFILM Diosynth Biotechnologies Main Business Overview
- 11.27.5 FUJIFILM Diosynth Biotechnologies Latest Developments
- 11.28 Groupe Parima
 - 11.28.1 Groupe Parima Company Information
 - 11.28.2 Groupe Parima Biologics and Biosimilars CXO Services Product Offered
 - 11.28.3 Groupe Parima Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.28.4 Groupe Parima Main Business Overview
 - 11.28.5 Groupe Parima Latest Developments
- 11.29 TBD Pharmatech
 - 11.29.1 TBD Pharmatech Company Information
 - 11.29.2 TBD Pharmatech Biologics and Biosimilars CXO Services Product Offered
 - 11.29.3 TBD Pharmatech Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.29.4 TBD Pharmatech Main Business Overview
 - 11.29.5 TBD Pharmatech Latest Developments
- 11.30 Avid Bioservices
 - 11.30.1 Avid Bioservices Company Information
 - 11.30.2 Avid Bioservices Biologics and Biosimilars CXO Services Product Offered
 - 11.30.3 Avid Bioservices Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.30.4 Avid Bioservices Main Business Overview
 - 11.30.5 Avid Bioservices Latest Developments
- 11.31 NextPharma
 - 11.31.1 NextPharma Company Information
 - 11.31.2 NextPharma Biologics and Biosimilars CXO Services Product Offered
 - 11.31.3 NextPharma Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
 - 11.31.4 NextPharma Main Business Overview
 - 11.31.5 NextPharma Latest Developments
- 11.32 Alcami
 - 11.32.1 Alcami Company Information
 - 11.32.2 Alcami Biologics and Biosimilars CXO Services Product Offered
 - 11.32.3 Alcami Biologics and Biosimilars CXO Services Revenue, Gross Margin and

Market Share (2021-2026)

11.32.4 Alcami Main Business Overview

11.32.5 Alcami Latest Developments

11.33 Societal CDMO

11.33.1 Societal CDMO Company Information

11.33.2 Societal CDMO Biologics and Biosimilars CXO Services Product Offered

11.33.3 Societal CDMO Biologics and Biosimilars CXO Services Revenue, Gross

Margin and Market Share (2021-2026)

11.33.4 Societal CDMO Main Business Overview

11.33.5 Societal CDMO Latest Developments

11.34 MedPharm

11.34.1 MedPharm Company Information

11.34.2 MedPharm Biologics and Biosimilars CXO Services Product Offered

11.34.3 MedPharm Biologics and Biosimilars CXO Services Revenue, Gross Margin

and Market Share (2021-2026)

11.34.4 MedPharm Main Business Overview

11.34.5 MedPharm Latest Developments

11.35 Euroapi

11.35.1 Euroapi Company Information

11.35.2 Euroapi Biologics and Biosimilars CXO Services Product Offered

11.35.3 Euroapi Biologics and Biosimilars CXO Services Revenue, Gross Margin and

Market Share (2021-2026)

11.35.4 Euroapi Main Business Overview

11.35.5 Euroapi Latest Developments

11.36 BioVectra

11.36.1 BioVectra Company Information

11.36.2 BioVectra Biologics and Biosimilars CXO Services Product Offered

11.36.3 BioVectra Biologics and Biosimilars CXO Services Revenue, Gross Margin

and Market Share (2021-2026)

11.36.4 BioVectra Main Business Overview

11.36.5 BioVectra Latest Developments

11.37 Pfizer CentreOne

11.37.1 Pfizer CentreOne Company Information

11.37.2 Pfizer CentreOne Biologics and Biosimilars CXO Services Product Offered

11.37.3 Pfizer CentreOne Biologics and Biosimilars CXO Services Revenue, Gross

Margin and Market Share (2021-2026)

11.37.4 Pfizer CentreOne Main Business Overview

11.37.5 Pfizer CentreOne Latest Developments

11.38 Fermion

- 11.38.1 Fermion Company Information
- 11.38.2 Fermion Biologics and Biosimilars CXO Services Product Offered
- 11.38.3 Fermion Biologics and Biosimilars CXO Services Revenue, Gross Margin and Market Share (2021-2026)
- 11.38.4 Fermion Main Business Overview
- 11.38.5 Fermion Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Biologics and Biosimilars CXO Services Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)

Table 2. Biologics and Biosimilars CXO Services Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of CRO

Table 4. Major Players of CDMO/CMO

Table 5. Major Players of CSO

Table 6. Biologics and Biosimilars CXO Services Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)

Table 7. Global Biologics and Biosimilars CXO Services Market Size by Type (2021-2026) & (\$ millions)

Table 8. Global Biologics and Biosimilars CXO Services Market Size Market Share by Type (2021-2026)

Table 9. Biologics and Biosimilars CXO Services Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)

Table 10. Global Biologics and Biosimilars CXO Services Market Size by Application (2021-2026) & (\$ millions)

Table 11. Global Biologics and Biosimilars CXO Services Market Size Market Share by Application (2021-2026)

Table 12. Global Biologics and Biosimilars CXO Services Revenue by Player (2021-2026) & (\$ millions)

Table 13. Global Biologics and Biosimilars CXO Services Revenue Market Share by Player (2021-2026)

Table 14. Biologics and Biosimilars CXO Services Key Players Head office and Products Offered

Table 15. Biologics and Biosimilars CXO Services Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 16. New Products and Potential Entrants

Table 17. Mergers & Acquisitions, Expansion

Table 18. Global Biologics and Biosimilars CXO Services Market Size by Region (2021-2026) & (\$ millions)

Table 19. Global Biologics and Biosimilars CXO Services Market Size Market Share by Region (2021-2026)

Table 20. Global Biologics and Biosimilars CXO Services Revenue by Country/Region (2021-2026) & (\$ millions)

Table 21. Global Biologics and Biosimilars CXO Services Revenue Market Share by Country/Region (2021-2026)

Table 22. Americas Biologics and Biosimilars CXO Services Market Size by Country (2021-2026) & (\$ millions)

Table 23. Americas Biologics and Biosimilars CXO Services Market Size Market Share by Country (2021-2026)

Table 24. Americas Biologics and Biosimilars CXO Services Market Size by Type (2021-2026) & (\$ millions)

Table 25. Americas Biologics and Biosimilars CXO Services Market Size Market Share by Type (2021-2026)

Table 26. Americas Biologics and Biosimilars CXO Services Market Size by Application (2021-2026) & (\$ millions)

Table 27. Americas Biologics and Biosimilars CXO Services Market Size Market Share by Application (2021-2026)

Table 28. APAC Biologics and Biosimilars CXO Services Market Size by Region (2021-2026) & (\$ millions)

Table 29. APAC Biologics and Biosimilars CXO Services Market Size Market Share by Region (2021-2026)

Table 30. APAC Biologics and Biosimilars CXO Services Market Size by Type (2021-2026) & (\$ millions)

Table 31. APAC Biologics and Biosimilars CXO Services Market Size by Application (2021-2026) & (\$ millions)

Table 32. Europe Biologics and Biosimilars CXO Services Market Size by Country (2021-2026) & (\$ millions)

Table 33. Europe Biologics and Biosimilars CXO Services Market Size Market Share by Country (2021-2026)

Table 34. Europe Biologics and Biosimilars CXO Services Market Size by Type (2021-2026) & (\$ millions)

Table 35. Europe Biologics and Biosimilars CXO Services Market Size by Application (2021-2026) & (\$ millions)

Table 36. Middle East & Africa Biologics and Biosimilars CXO Services Market Size by Region (2021-2026) & (\$ millions)

Table 37. Middle East & Africa Biologics and Biosimilars CXO Services Market Size by Type (2021-2026) & (\$ millions)

Table 38. Middle East & Africa Biologics and Biosimilars CXO Services Market Size by Application (2021-2026) & (\$ millions)

Table 39. Key Market Drivers & Growth Opportunities of Biologics and Biosimilars CXO Services

Table 40. Key Market Challenges & Risks of Biologics and Biosimilars CXO Services

- Table 41. Key Industry Trends of Biologics and Biosimilars CXO Services
- Table 42. Global Biologics and Biosimilars CXO Services Market Size Forecast by Region (2027-2032) & (\$ millions)
- Table 43. Global Biologics and Biosimilars CXO Services Market Size Market Share Forecast by Region (2027-2032)
- Table 44. Global Biologics and Biosimilars CXO Services Market Size Forecast by Type (2027-2032) & (\$ millions)
- Table 45. Global Biologics and Biosimilars CXO Services Market Size Forecast by Application (2027-2032) & (\$ millions)
- Table 46. Catalent Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors
- Table 47. Catalent Biologics and Biosimilars CXO Services Product Offered
- Table 48. Catalent Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 49. Catalent Main Business
- Table 50. Catalent Latest Developments
- Table 51. Thermo Fisher Scientific Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors
- Table 52. Thermo Fisher Scientific Biologics and Biosimilars CXO Services Product Offered
- Table 53. Thermo Fisher Scientific Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 54. Thermo Fisher Scientific Main Business
- Table 55. Thermo Fisher Scientific Latest Developments
- Table 56. Lonza Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors
- Table 57. Lonza Biologics and Biosimilars CXO Services Product Offered
- Table 58. Lonza Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 59. Lonza Main Business
- Table 60. Lonza Latest Developments
- Table 61. Siegfried Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors
- Table 62. Siegfried Biologics and Biosimilars CXO Services Product Offered
- Table 63. Siegfried Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 64. Siegfried Main Business
- Table 65. Siegfried Latest Developments
- Table 66. Recipharm Details, Company Type, Biologics and Biosimilars CXO Services

Area Served and Its Competitors

Table 67. Recipharm Biologics and Biosimilars CXO Services Product Offered

Table 68. Recipharm Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 69. Recipharm Main Business

Table 70. Recipharm Latest Developments

Table 71. Boehringer Ingelheim Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 72. Boehringer Ingelheim Biologics and Biosimilars CXO Services Product Offered

Table 73. Boehringer Ingelheim Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 74. Boehringer Ingelheim Main Business

Table 75. Boehringer Ingelheim Latest Developments

Table 76. WuXi AppTech Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 77. WuXi AppTech Biologics and Biosimilars CXO Services Product Offered

Table 78. WuXi AppTech Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 79. WuXi AppTech Main Business

Table 80. WuXi AppTech Latest Developments

Table 81. WuXi Biologics Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 82. WuXi Biologics Biologics and Biosimilars CXO Services Product Offered

Table 83. WuXi Biologics Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 84. WuXi Biologics Main Business

Table 85. WuXi Biologics Latest Developments

Table 86. Fareva Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 87. Fareva Biologics and Biosimilars CXO Services Product Offered

Table 88. Fareva Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 89. Fareva Main Business

Table 90. Fareva Latest Developments

Table 91. Samsung Biologics Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 92. Samsung Biologics Biologics and Biosimilars CXO Services Product Offered

Table 93. Samsung Biologics Biologics and Biosimilars CXO Services Revenue (\$

million), Gross Margin and Market Share (2021-2026)

Table 94. Samsung Biologics Main Business

Table 95. Samsung Biologics Latest Developments

Table 96. Aenova Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 97. Aenova Biologics and Biosimilars CXO Services Product Offered

Table 98. Aenova Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 99. Aenova Main Business

Table 100. Aenova Latest Developments

Table 101. Delpharm Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 102. Delpharm Biologics and Biosimilars CXO Services Product Offered

Table 103. Delpharm Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 104. Delpharm Main Business

Table 105. Delpharm Latest Developments

Table 106. Strides Pharma Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 107. Strides Pharma Biologics and Biosimilars CXO Services Product Offered

Table 108. Strides Pharma Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 109. Strides Pharma Main Business

Table 110. Strides Pharma Latest Developments

Table 111. Piramal Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 112. Piramal Biologics and Biosimilars CXO Services Product Offered

Table 113. Piramal Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 114. Piramal Main Business

Table 115. Piramal Latest Developments

Table 116. Famar Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 117. Famar Biologics and Biosimilars CXO Services Product Offered

Table 118. Famar Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 119. Famar Main Business

Table 120. Famar Latest Developments

Table 121. Curia Details, Company Type, Biologics and Biosimilars CXO Services Area

Served and Its Competitors

Table 122. Curia Biologics and Biosimilars CXO Services Product Offered

Table 123. Curia Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 124. Curia Main Business

Table 125. Curia Latest Developments

Table 126. Jubilant Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 127. Jubilant Biologics and Biosimilars CXO Services Product Offered

Table 128. Jubilant Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 129. Jubilant Main Business

Table 130. Jubilant Latest Developments

Table 131. Vetter Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 132. Vetter Biologics and Biosimilars CXO Services Product Offered

Table 133. Vetter Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 134. Vetter Main Business

Table 135. Vetter Latest Developments

Table 136. AGC Pharma Chemicals Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 137. AGC Pharma Chemicals Biologics and Biosimilars CXO Services Product Offered

Table 138. AGC Pharma Chemicals Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 139. AGC Pharma Chemicals Main Business

Table 140. AGC Pharma Chemicals Latest Developments

Table 141. Asymchem Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 142. Asymchem Biologics and Biosimilars CXO Services Product Offered

Table 143. Asymchem Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 144. Asymchem Main Business

Table 145. Asymchem Latest Developments

Table 146. Pharmaron Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 147. Pharmaron Biologics and Biosimilars CXO Services Product Offered

Table 148. Pharmaron Biologics and Biosimilars CXO Services Revenue (\$ million),

Gross Margin and Market Share (2021-2026)

Table 149. Pharmaron Main Business

Table 150. Pharmaron Latest Developments

Table 151. Eurofins Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 152. Eurofins Biologics and Biosimilars CXO Services Product Offered

Table 153. Eurofins Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 154. Eurofins Main Business

Table 155. Eurofins Latest Developments

Table 156. Ascendia Pharmaceuticals Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 157. Ascendia Pharmaceuticals Biologics and Biosimilars CXO Services Product Offered

Table 158. Ascendia Pharmaceuticals Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 159. Ascendia Pharmaceuticals Main Business

Table 160. Ascendia Pharmaceuticals Latest Developments

Table 161. Ardena Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 162. Ardena Biologics and Biosimilars CXO Services Product Offered

Table 163. Ardena Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 164. Ardena Main Business

Table 165. Ardena Latest Developments

Table 166. CPL Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 167. CPL Biologics and Biosimilars CXO Services Product Offered

Table 168. CPL Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 169. CPL Main Business

Table 170. CPL Latest Developments

Table 171. UPM Pharmaceuticals Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 172. UPM Pharmaceuticals Biologics and Biosimilars CXO Services Product Offered

Table 173. UPM Pharmaceuticals Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 174. UPM Pharmaceuticals Main Business

- Table 175. UPM Pharmaceuticals Latest Developments
- Table 176. FUJIFILM Diosynth Biotechnologies Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors
- Table 177. FUJIFILM Diosynth Biotechnologies Biologics and Biosimilars CXO Services Product Offered
- Table 178. FUJIFILM Diosynth Biotechnologies Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 179. FUJIFILM Diosynth Biotechnologies Main Business
- Table 180. FUJIFILM Diosynth Biotechnologies Latest Developments
- Table 181. Groupe Parima Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors
- Table 182. Groupe Parima Biologics and Biosimilars CXO Services Product Offered
- Table 183. Groupe Parima Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 184. Groupe Parima Main Business
- Table 185. Groupe Parima Latest Developments
- Table 186. TBD Pharmatech Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors
- Table 187. TBD Pharmatech Biologics and Biosimilars CXO Services Product Offered
- Table 188. TBD Pharmatech Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 189. TBD Pharmatech Main Business
- Table 190. TBD Pharmatech Latest Developments
- Table 191. Avid Bioservices Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors
- Table 192. Avid Bioservices Biologics and Biosimilars CXO Services Product Offered
- Table 193. Avid Bioservices Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 194. Avid Bioservices Main Business
- Table 195. Avid Bioservices Latest Developments
- Table 196. NextPharma Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors
- Table 197. NextPharma Biologics and Biosimilars CXO Services Product Offered
- Table 198. NextPharma Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 199. NextPharma Main Business
- Table 200. NextPharma Latest Developments
- Table 201. Alcami Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

- Table 202. Alcami Biologics and Biosimilars CXO Services Product Offered
- Table 203. Alcami Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 204. Alcami Main Business
- Table 205. Alcami Latest Developments
- Table 206. Societal CDMO Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors
- Table 207. Societal CDMO Biologics and Biosimilars CXO Services Product Offered
- Table 208. Societal CDMO Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 209. Societal CDMO Main Business
- Table 210. Societal CDMO Latest Developments
- Table 211. MedPharm Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors
- Table 212. MedPharm Biologics and Biosimilars CXO Services Product Offered
- Table 213. MedPharm Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 214. MedPharm Main Business
- Table 215. MedPharm Latest Developments
- Table 216. Euroapi Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors
- Table 217. Euroapi Biologics and Biosimilars CXO Services Product Offered
- Table 218. Euroapi Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 219. Euroapi Main Business
- Table 220. Euroapi Latest Developments
- Table 221. BioVectra Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors
- Table 222. BioVectra Biologics and Biosimilars CXO Services Product Offered
- Table 223. BioVectra Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 224. BioVectra Main Business
- Table 225. BioVectra Latest Developments
- Table 226. Pfizer CentreOne Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors
- Table 227. Pfizer CentreOne Biologics and Biosimilars CXO Services Product Offered
- Table 228. Pfizer CentreOne Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 229. Pfizer CentreOne Main Business

Table 230. Pfizer CentreOne Latest Developments

Table 231. Fermion Details, Company Type, Biologics and Biosimilars CXO Services Area Served and Its Competitors

Table 232. Fermion Biologics and Biosimilars CXO Services Product Offered

Table 233. Fermion Biologics and Biosimilars CXO Services Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 234. Fermion Main Business

Table 235. Fermion Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Biologics and Biosimilars CXO Services Report Years Considered
- Figure 2. Research Objectives
- Figure 3. Research Methodology
- Figure 4. Research Process and Data Source
- Figure 5. Global Biologics and Biosimilars CXO Services Market Size Growth Rate (2021-2032) (\$ millions)
- Figure 6. Biologics and Biosimilars CXO Services Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 7. Biologics and Biosimilars CXO Services Sales Market Share by Country/Region (2025)
- Figure 8. Biologics and Biosimilars CXO Services Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 9. Global Biologics and Biosimilars CXO Services Market Size Market Share by Type in 2025
- Figure 10. Biologics and Biosimilars CXO Services in API CXO
- Figure 11. Global Biologics and Biosimilars CXO Services Market: API CXO (2021-2026) & (\$ millions)
- Figure 12. Biologics and Biosimilars CXO Services in FDF CXO
- Figure 13. Global Biologics and Biosimilars CXO Services Market: FDF CXO (2021-2026) & (\$ millions)
- Figure 14. Biologics and Biosimilars CXO Services in Other
- Figure 15. Global Biologics and Biosimilars CXO Services Market: Other (2021-2026) & (\$ millions)
- Figure 16. Global Biologics and Biosimilars CXO Services Market Size Market Share by Application in 2025
- Figure 17. Global Biologics and Biosimilars CXO Services Revenue Market Share by Player in 2025
- Figure 18. Global Biologics and Biosimilars CXO Services Market Size Market Share by Region (2021-2026)
- Figure 19. Americas Biologics and Biosimilars CXO Services Market Size 2021-2026 (\$ millions)
- Figure 20. APAC Biologics and Biosimilars CXO Services Market Size 2021-2026 (\$ millions)
- Figure 21. Europe Biologics and Biosimilars CXO Services Market Size 2021-2026 (\$ millions)

Figure 22. Middle East & Africa Biologics and Biosimilars CXO Services Market Size 2021-2026 (\$ millions)

Figure 23. Americas Biologics and Biosimilars CXO Services Value Market Share by Country in 2025

Figure 24. United States Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 25. Canada Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 26. Mexico Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 27. Brazil Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 28. APAC Biologics and Biosimilars CXO Services Market Size Market Share by Region in 2025

Figure 29. APAC Biologics and Biosimilars CXO Services Market Size Market Share by Type (2021-2026)

Figure 30. APAC Biologics and Biosimilars CXO Services Market Size Market Share by Application (2021-2026)

Figure 31. China Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 32. Japan Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 33. South Korea Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 34. Southeast Asia Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 35. India Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 36. Australia Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 37. Europe Biologics and Biosimilars CXO Services Market Size Market Share by Country in 2025

Figure 38. Europe Biologics and Biosimilars CXO Services Market Size Market Share by Type (2021-2026)

Figure 39. Europe Biologics and Biosimilars CXO Services Market Size Market Share by Application (2021-2026)

Figure 40. Germany Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 41. France Biologics and Biosimilars CXO Services Market Size Growth

2021-2026 (\$ millions)

Figure 42. UK Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 43. Italy Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 44. Russia Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 45. Middle East & Africa Biologics and Biosimilars CXO Services Market Size Market Share by Region (2021-2026)

Figure 46. Middle East & Africa Biologics and Biosimilars CXO Services Market Size Market Share by Type (2021-2026)

Figure 47. Middle East & Africa Biologics and Biosimilars CXO Services Market Size Market Share by Application (2021-2026)

Figure 48. Egypt Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 49. South Africa Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 50. Israel Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 51. Turkey Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 52. GCC Countries Biologics and Biosimilars CXO Services Market Size Growth 2021-2026 (\$ millions)

Figure 53. Americas Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 54. APAC Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 55. Europe Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 56. Middle East & Africa Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 57. United States Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 58. Canada Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 59. Mexico Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 60. Brazil Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 61. China Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 62. Japan Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 63. Korea Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 64. Southeast Asia Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 65. India Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 66. Australia Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 67. Germany Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 68. France Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 69. UK Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 70. Italy Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 71. Russia Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 72. Egypt Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 73. South Africa Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 74. Israel Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 75. Turkey Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

Figure 76. Global Biologics and Biosimilars CXO Services Market Size Market Share Forecast by Type (2027-2032)

Figure 77. Global Biologics and Biosimilars CXO Services Market Size Market Share Forecast by Application (2027-2032)

Figure 78. GCC Countries Biologics and Biosimilars CXO Services Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global Biologics and Biosimilars CXO Services Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/GDFF12F7397BEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDFF12F7397BEN.html>